AACR: Results of THYME Trial Show the Time Is Not Right for AZD8931

The THYME trial testing AZD8931 in advanced HER2-low breast cancer failed to reach the primary endpoint of progression-free survival, according to results of the phase II trial presented at the 2013 AACR meeting in Washington, DC.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news